Sandeep Jagtap: Presenting the Research Behind Pediatric Fondaparinux at ISTH 2026
Sandeep Jagtap, Senior Director, Global Clinical Strategy and Innovation at Viatris, shared a pos on LinkedIn:
“Some scientific moments stay with you for a long time.
It was truly special to present one of our most cherished pieces of work at ISTH 2026 in Paris. This research on Arixtra (fondaparinux) contributed to its FDA approval for pediatric venous thromboembolism patients, helping address an area of significant unmet medical need.
Presenting this work on such a prestigious global platform was both humbling and deeply rewarding.
I am sincerely grateful to all the colleagues, investigators, and collaborators whose dedication and contributions made this work possible. It was a proud and memorable moment to see years of collective effort translated into meaningful progress for children.”
Stay Updated with the Latest ISTH 2026 Updates on Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026